Glucotrack has successfully completed a first-in-human study with its continuous glucose monitor (CGM) that directly measures ...

RUTHERFORD, NJ - Glucotrack, Inc. (NASDAQ:GCTK), a developer of medical technologies for diabetes care, has announced the pricing of its public offering at $1.15 per share, aiming to raise ...

Glucotrack (GCTK) reports successful completion of first human clinical study for continuous blood glucose monitoring, shares ...

RUTHERFORD, N.J. - Glucotrack, Inc. (NASDAQ: GCTK), a medical technology company, announced the successful completion of its first in human clinical study for a novel continuous glucose monitoring ...

This study represents the first real-time, continuous blood glucose monitor (CBGM) placed in the subclavian vein, offering the potential for direct blood glucose measurement without the limitations ...

Glucotrack (Nasdaq:GCTK) announced today that it completed the first-in-human clinical study of its continuous blood glucose ...

Glucotrack (GCTK) announced the successful completion of its first in human clinical study, marking a significant milestone in continuous ...

For athletes with diabetes, continuous glucose monitors are game-changers, helping them avoid dangerous blood sugar crashes ...

The remote patient monitoring (RPM) technology that a patient uses while receiving hospital-at-home care does not follow a ...

New research suggests that wearing continuous glucose monitors could lower the risk of dementia. Experts discuss how symptoms ...

The bull market of the past year or more has reinvigorated investors' interest across a range of industries, and the performance of many top stocks reflects this reality. DexCom (NASDAQ: DXCM) is one ...

When you buy through our links, we may earn a commission. Learn more› By Dave Gershgorn Dave Gershgorn is a writer covering monitors, laptops, and tablets. He is a certified display calibrator ...